MedTrace Logo

Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

NCT01117454 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2017-06-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test whether the addition of oral flecainide to standard therapy will reduce ventricular ectopy on exercise test compared to placebo plus standard therapy in patients with Catecholaminergic Polymorphic Ventricular Tachycardia.

Conditions

  • Catecholaminergic Polymorphic Ventricular Tachycardia

Interventions

DRUG

Flecainide Acetate

oral flecainide with the dose titrated to achieve a serum level between 0.5-0.8 mcg/ml

DRUG

Placebo

placebo, similar in appearance to flecainide

DRUG

Beta blocker

Standard therapy with beta-blocker (nadolol, atenolol, metoprolol, or propranolol) continues throughout the trial.

Sponsors & Collaborators

  • Vanderbilt University Medical Center

    lead OTHER

Principal Investigators

  • Prince J Kannankeril, MD, MSCI · Vanderbilt University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
5 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01117454 on ClinicalTrials.gov